数字监测用药依从性与肺功能指导未控制哮喘管理(INCA Sun):多中心单盲随机临床试验
INCA Sun 是一项在爱尔兰、北爱尔兰和英格兰十家重度哮喘诊所开展的多中心、单盲、随机对照试验,纳入 213 例未控制哮喘患者,比较基于数字依从性、吸入技术和峰流速数据指导治疗调整与常规方法的效果。
要点
- 数字数据指导治疗可减少未控制哮喘患者的治疗负担。
- 两组严重不良事件均与研究干预无因果关联。
核心结论
- 基于数字数据的循证护理使哮喘用药依从性适度改善,并显著降低治疗负担。
研究设计与样本
- 32 周前瞻性、多中心、单盲、平行随机对照试验,在爱尔兰、北爱尔兰和英格兰十家重度哮喘诊所开展。
- 共筛查 425 例,220 例同意,213 例随机分配(活性组 n=108,对照组 n=105),200 例完成研究(活性组 n=102,对照组 n=98)。
- 纳入 18 岁及以上、未控制哮喘、ACT 评分≤19、尽管使用高剂量吸入糖皮质激素且过去一年至少一次严重急性发作的患者。
- 按 1:1 随机分配,采用计算机生成、可变区组大小(2、4、6)的置换区组序列,按 FeNO 浓度和招募中心分层。
临床怎么用
- 对使用高剂量吸入糖皮质激素仍未控制的重度哮喘患者,可考虑将数字依从性、吸入技术和峰流速数据纳入治疗调整决策。
- 数字数据指导有助于减少不必要的治疗升级,并支持在适当患者中减少吸入糖皮质激素剂量。
局限性
- 单盲设计,对照组患者对依从性和吸入技术错误数据设盲,但医生治疗调整未设盲。
- 研究仅在爱尔兰、北爱尔兰和英格兰的重度哮喘诊所开展,外推性需谨慎。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The clinical value of using digital tools to assess adherence and lung function in uncontrolled asthma is not known. We aimed to compare treatment decisions guided by digitally acquired data on adherence, inhaler technique, and peak flow with existing methods. METHODS: A 32-week prospective, multicentre, single-blinded, parallel, randomly controlled trial was done in ten severe asthma clinics across Ireland, Northern Ireland, and England. Participants were 18 years or older, had uncontrolled asthma, asthma control test (ACT) score of 19 or less, despite treatment with high-dose inhaled corticosteroids, and had at least one severe exacerbation in the past year despite high-dose inhaled corticosteroids. Patients were randomly assigned in a 1:1 ratio to the active group or the control group, by means of a computer-generated randomisation sequence of permuted blocks of varying sizes (2, 4, and 6) stratified by fractional exhaled nitric oxide (FeNO) concentration and recruitment site. In the control group, participants were masked to their adherence and errors in inhaler technique data. A statistician masked to study allocation did the statistical analysis. After a 1-week run-in period, both groups attended three nurse-led education visits over 8 weeks (day 7, week 4, and week 8) and three physician-led treatment adjustment visits at weeks 8, 20, and 32. In the active group, treatment adjustments during the physician visits were informed by digital data on inhaler adherence, twice daily digital peak expiratory flow (ePEF), patient-reported asthma control, and exacerbation history. Treatment was adjusted in the control group on the basis of pharmacy refill rates (a measure of adherence), asthma control by ACT questionnaire, and history of exacerbations and visual management of inhaler technique. Both groups used a digitally enabled Inhaler Compliance Assessment (INCA) and PEF. The primary outcomes were asthma medication burden measured as proportion of patients who required a net increase in treatment at the end of 32 weeks and adherence rate measured in the last 12 weeks by area under the curve in the intention-to-treat population. The safety analyses included all patients who consented for the trial. The trial is registered with ClinicalTrials.gov, NCT02307669 and is complete. FINDINGS: Between Oct 25, 2015, and Jan 26, 2020, of 425 patients assessed for eligibility, 220 consented to participate in the study, 213 were randomly assigned (n=108 in the active group; n=105 in the control group) and 200 completed the study (n=102 in the active group; n=98 in the control group). In the intention-to-treat analysis at week 32, 14 (14%) active and 31 (32%) control patients had a net increase in treatment compared with baseline (odds ratio [OR] 0·31 [95% CI 0·15-0·64], p=0·0015) and 11 (11%) active and 21 (21%) controls required add-on biological therapy (0·42 [0·19-0·95], p=0·038) adjusted for study site, age, sex, and baseline FeNO. Three (16%) of 19 active and 11 (44%) of 25 control patients increased their medication from fluticasone propionate 500 μg daily to 1000 μg daily (500 μg twice a day; adjusted OR 0·23 [0·06-0·87], p=0·026). 26 (31%) of 83 active and 13 (18%) of 73 controls reduced their medication from fluticasone propionate 1000 μg once daily to 500 μg once daily (adjusted OR 2·43 [1·13-5·20], p=0·022. Week 20-32 actual mean adherence was 64·9% (SD 23·5) in the active group and 55·5% (26·8) in the control group (between-group difference 11·1% [95% CI 4·4-17·9], p=0·0012). A total of 29 serious adverse events were recorded (16 [55%] in the active group, and 13 [45%] in the control group), 11 of which were confirmed as respiratory. None of the adverse events reported were causally linked to the study intervention, to the use of salmeterol-fluticasone inhalers, or the use of the digital PEF or INCA. INTERPRETATION: Evidence-based care informed by digital data led to a modest improvement in medication adherence and a significantly lower treatment burden. FUNDING: Health Research Board of Ireland, Medical Research Council, INTEREG Europe, and an investigator-initiated project grant from GlaxoSmithKline.
引用
- Hale, Greene, Mulvey, et al. Use of digital measurement of medication adherence and lung function to guide the management of uncontrolled asthma (INCA Sun): a multicentre, single-blinded, randomised clinical trial. Lancet Respir Med. 2023. PMID: 36963417. doi:10.1016/S2213-2600(22)00534-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。